Many insurance plans may cover your visit
By binding to GLP-1 receptors in the brain, Semaglutide reduces appetite and increases feelings of fullness, making it easier to stick to a healthy diet and exercise plan
Contact your healthcare provider immediately if you experience: Severe, persistent abdominal pain (could indicate pancreatitis, gallbladder disease, or surgical complications) Persistent vomiting preventing fluid intake (risk of dehydration and acute kidney injury) Signs of dehydration (dark urine, dizziness, reduced urination) Symptoms of hypoglycaemia if taking other diabetes medications Unusual fatigue, fever, or wound-related concerns The Ozempic SmPC specifically mentions pancreatitis and gallbladder disease as potential risks that require prompt medical attention
The jumps between phases are larger than standard protocols, moving from 0.40 mg directly to 0.90 mg rather than the traditional 0.50 mg to 1.00 mg step
Dehydration represents a clinically significant risk for patients taking GLP-1 medications, particularly during the initial weeks of therapy or following dose increases when gastrointestinal side effects are most pronounced
